The Levels of Granulocyte Colony-Stimulating Factor in the Plasma of the Bone Marrow Aspirate in Various Hematological Disorders
|
|
- Roxanne Shelton
- 5 years ago
- Views:
Transcription
1 The Levels of Granulocyte Colony-Stimulating Factor in the Plasma of the Bone Marrow Aspirate in Various Hematological Disorders Kenji Shinohara,a Eiichi Oeda,a Jun Nomiyama,a Hirofumi Inoue; Shinji Kamei,b Mitsuaki Tajirtb Takanori Ichikawa," Tomoki Kuwaki," Katsunori Tachibanac "Division of Hematology, Department of Medicine, Yamaguchi Prefecture Central Hospital, Hofu, Japan; bdepartment of Medicine, Shuto General Hospital, Yanai, Japan; 'Pharmaceutical Development Laboratory and Pharmaceutical Research Laboratory, Kirin Brewery Co., Ltd., Takasaki, Japan Key Words. Granulocyte colony-stimulating factor (G-CSF) Bone marrow Plasma Hematological disorder Abstract. We developed a sensitive method of measurement of granulocyte colony-stimulating factor (G-CSF) by an enzyme-linked immunosorbent assay, which we applied in the plasma of the bone marrow aspirate in 70 patients with various hematological disorders. The lowest limit of detection by this method is 2 pg/ml. G-CSF was detected in all but two of the patients. Compared to the G-CSF level in normal healthy controls, those in non- Hodgkin's malignant lymphoma, aplastic anemia, agranulocytosis and multiple myeloma were significantly higher, while the level in refractory anemia was not different. The G-CSF level in acute myelogenous leukemia patients was either elevated or decreased regardless of the French-American- British subgroup. The level in acute lymphoblastic leukemia was not different from the normal value, as was that in refractory anemia with an excess of blasts, and that in chronic lymphocytic leukemia. A patient with chronic myelomonocytic leukemia showed initial elevation of G-CSF with normalization after entering complete remission. The G-CSF level in chronic myelogenous leukemia was significantly decreased, although one patient in hematological remission who was under a-interferon therapy showed normal levels. The level in polycythemia Vera was not significantly different from the normal value. The G-CSF level for the entire group showed an inverse, although not statistically significant, correlation with the percentages of myeloid cells of the bone marrow (r = , p = 0.170, n = 80). These results are thought to reflect the regulatory mechanism of granulopoiesis in the bone marrow in various hematological disorders, Correspondence: Dr. Kenji Shinohara, Division of Hematology, Department of Medicine, Yamaguchi Prefecture Central Hospital, Hofu 747, Japan. Received January 18, 1995; provisionally accepted February 24, 1995; accepted for publication March 1, OAlphaMed Press /95/$5.OO/O and it is concluded that this method may be of dinical use in the treatment of patients with these disorders and in the selection of candidates likely to benefit from G-CSF administration. Introduction Granulocyte colony-stimulating factor (G-CSF) is secreted by the stromal macrophages, endothelial cells and fibroblasts in the bone marrow (BM) in response to several types of stimuli [l-1. Hematopoietic stem cells proliferate and differentiate in the BM, and mature cells are mobilized into circulation in response to hematopoietic growth factors. G- CSF acts not only as a circulating hormone but also acts locally as a paracrine hormone in areas such as BM. Although several methods of measuring peripheral blood serum G-CSF levels have been reported, the sensitivity of these methods is not high enough to allow detection of the concentration in all healthy controls and in patients with various hematological disorders [4-81. We developed a method of measuring G- CSF concentrations using the 2-step sandwich enzyme-linked immunosorbent assay (ELISA) [9], and measured those concentrations in the plasma of BM aspirate since there are no other reports of a measurement of G-CSF concentration in the BM plasma. This method is sufficiently sensitive to allow detection in the plasma of the BM aspirate in almost all patients with various hematological disorders. In comparison with those measured in the peripheral blood serum, the results obtained using this method are thought to more sensitively and directly STEM CELLS 1995;1:
2 Shinohara et al. 422 reflect the regulatory mechanism modulating the relationship between the production of G-CSF and the response of hematopoietic stem cells in the various pathological granulopoietic conditions, and to provide more information regarding the clinical significance of G-CSF in hematological disorders. Materials and Methods Patients The subjects included 70 patients with various hematological disorders, as follows: 12 with aplastic anemia (AA), each with non- Hodgkin s malignant lymphoma (ML) and acute myelogenous leukemia (AML), 9 with multiple myeloma (MM), 7 with refractory anemia (RA), 6 with chronic myelogenous leukemia (CML), each with agranulocytosis (Agra), acute lymphoblastic leukemia (ALL), refractory anemia with excess of blasts (RAEB), chronic lymphocytic leukemia (CLL) and polycythemia Vera (PV) and one with chronic myelomonocytic leukemia (CMML). In addition, plasma samples from the normal control were also evaluated. The AML patients consisted of 2 with MO, 1 each with MI and M2,4 with M4, 1 with M5 and 1 with hybrid leukemia according to the French-American-British (FAB) classification. The patients with ML were at the clinical stages I and I1 according to the Ann Arbor classification; some patients had received previous chemotherapy, and all of the patients were hematologically normal at the time of this study. The patients with AA and RA showed moderate to severe grades of severity; some of these received anabolic steroids and showed improvement in the Hb level, but not in leukocytes, granulocytes or platelets. None of the patients with MM, AML, ALL, RAEB, CMML, CLL, CML or PV had received any previous chemotherapy. Some of the patients with CML had received a-interferon, and one was in hematological remission. None of the patients had infection at the time of this study except two patients with Agra who had fever due to infection. Methods The BM was aspirated from the patient after informed consent was obtained. Since the BM aspirate plasma may become diluted with peripheral blood plasma, we attempted to aspirate only about 2 to ml of BM aspirate. It was difficult to obtain plasma in less than this volume of BM aspirate, because of the sticky nature of plasma, due to the presence of fat and fibrous tissue. We did not measure the G-CSF levels simultaneously in the peripheral blood in all of the patients, which had already been measured in several reported studies [4-81. In our preliminary study of simultaneous measurements in the peripheral blood plasma and BM plasma in a limited number of patients, G-CSF levels were well-correlated (r = 0.954, n = 12, data not shown). We did not quantify the number of cells in the BM aspirate since the method is not always reliable in view of the variable cellularity of BM [lo], but rather measured the percentage of myeloid cells in the BM smear to approximately measure the conditions of granulopoiesis. The heparinized BM plasma was obtained by centrifugation of the aspirate. The concentration of G-CSF was measured using a modified 2-step sandwich ELISA method [9]. Briefly, 96-well microliter plates were coated with anti-g-csf monoclonal antibody immunoglobulin G (IgG) and left overnight at 4 C. The plates were then washed and blocked by incubation with skim milk solution. After washing, BM plasma samples and G-CSF standard solutions were then added to the plates and incubated for 5 h at room temperature. The plates were then washed, and the solution containing anti-g-csf polyclonal antibody (FAB ) conjugated with P-galactosidase was added to the plates and further incubated overnight at 4 C. After washing, fluorescence substrate solution (4-methyllumbelliferyl-~-D-galactoside) was added to the plates and reacted for 6 h at 7 C. The reaction was stopped by addition of glycine- NAOH buffer (ph.), and fluorescence intensity was measured at the excitation wavelength of 50 nm and absorbance emission wavelength of 460 nm. The G-CSF level was determined with reference to the standard graph using known concentrations of recombinant G-CSF (Fig. 1). The variability of the assay was of minimum range. The data were analyzed according to the Wilcoxon 2-sample test. Results The lowest concentration of G-CSF in the BM plasma detectable by our method was found
3 42 The Levels of G-CSF in the Plasma of the Bone Marrow Aspirate in Various Hematological Disorders AML patients, there was no correlation 0.01 I Concentration of G-CSF (pglml) Fig. 1. The standard graph for determination of G-CSF concentration. Recombinant G-CSF of known concentration was used as the standard solution. to be 2 pg/ml. The G-CSF levels, mean and standard error of mean (SE) in normal controls and in each group of patients are shown in Table I. The level of BM plasma G-CSF in normal controls was pg/ml, and was higher than that from our results (.5 _+ 0.6 pg/ml) for the peripheral blood serum of normal controls (p < 0.01) [9]. The G-CSF level reported hereafter for each group is that compared with the level for normal controls. The G-CSF values in ML were significantly higher (p < 0.01). The G-CSF values in the patients with AA and MM showed a wide range, but the values were significantly higher (both, p < 0.01). Values in RA, ALL, RAEB, CLL and PV were not significantly different. The G-CSF value was extremely high in two of the three Agra < 0.05). Of the patients with AML, 2 with MO and 1 each with M4 and M5 showed an elevated G-CSF level, while 1 each with MI, M2 and hybrid leukemia and with M4 showed reduced G-CSF values. In the between the percentage of leukemic blasts and G-CSF level (Fig. 2). The G-CSF level in the CMML patient was high, but returned to normal (. pg/ml) after complete remission was entered. The G-CSF level for the CML patients was significantly reduced (p < 0.05), although one patient in hematological remission who was under a-interferon therapy had normal levels. In general, the G-CSF levels of the BM plasma in the patients with hematological disorders and normal controls were inversely correlated with the percentages of BM myeloid cells in the smears although not statistically significant (r = , p = 0.170, n = 80) (Fig. ). An inverse, although statistically not significant, correlation was also observed in AA patients (r = , p = , n = 12) (Fig. 4). Table I. The levels of G-CSF in the plasma of the BM aspirates in patients with various hematological disorders Diagnosis Number SE p value* Normal Control ML AA RA Agra MM AML ALL RAEB CMML CLL CML PV < 0.01 < 0.01 < 0.05 < 0.01 < 0.05 *compared to normal controls : not significant Data are expressed as mean * SE. The p values are those for comparison with the normal controls
4 Shinohara et al. 424 G-CSF(p(yml) r= p= 0.8 n= G-CSF(pg/ml) 1 ooooj 1 00 A 1 I= p= n= Bone Marrow Myeloid Cells (Yo) I, I I I,,,,, Bone Marrow Mveloblasts (%I Fig. 4. The G-CSF levels and the percentage of myeloid cells in the BM in the patients with AA. An inverse correlation was observed. Discussion Fig. 2. The G-CSF levels and the percentage of leukemic myeloblasts in the BM in patients with AML. MO, M1, M2, M4 and M5 denote the subgroups of AML according to the FAB classification. Hy denotes hybrid leukemia. No correlation was observed. G-CSF(W/ml) r= x Normal 0 ML AAP A 'mo~o p= ) I.t( *MI 0 am.i mu1 0 20,, ,, I, Bone Marrow Myeloid Cells (%) Fig.. The G-CSF levels and the percentage of myeloid cells in the BM in normal control and various hematological disorders. An inverse correlation was observed. The detection limit of previously reported methods for measuring peripheral blood serum ranges from pg/ml to 0-50 pg/ml [4-81, and with these methods the G-CSF level could be measured in only a minority of normal controls and in some, but not all patients, remaining undetectable in the rest. Because of the increased sensitivity of measurement of our method, the BM plasma G-CSF levels could be measured in all except two of the patients. The patients showed a wide range in the G-CSF levels in BM plasma. The levels in the patients with non-hodgkin's lymphoma were higher than the normal control levels. In most of the patients with ML, the peripheral blood serum G-CSF level was not high and was below the detection limit [6]. There may have been an effect of the past chemotherapies on granulopoiesis in some patients, since peripheral blood serum level has been observed to increase during chemotherapy or preconditioning-induced neutropenia and to decrease following the granulocyte recovery phase after chemotherapy [5, 61 and BM transplantation [7, 8, 1 I]. The G-CSF level of AA patients is reported to be elevated in the peripheral blood serum; of 6 patients had elevated levels [5], and the mean level was 260 pg/ml [6]. We also observed elevated values, but the G-CSF level in the BM
5 425 The Levels of G-CSF in the Plasma of the Bone Marrow Aspirate in Various Hematological Disorders plasma was not so high as compared with that in the peripheral blood serum. Subtle changes of the G-CSF concentration in the BM plasma may more directly reflect the effects of the process of granulopoiesis in the BM. The peripheral blood serum G-CSF level in the AA patients was inversely correlated with the absolute neutrophil count [6], while we also observed a similar tendency between the BM plasma G-CSF level and the percentages of myeloid cells in the BM aspirate smears. The clinical use of erythropoietin (Epo) in patients with AA has not always had successful results [ 121, since the endogenous production of Epo is extremely high in many of these patients; the mean value was one hundred times higher than the normal value 111. Our results in turn suggest that G-CSF may be clinically more useful than Epo, and that exogenously administered G-CSF may increase the blood G-CSF levels and stimulate granulopoiesis if responding hematopojetic stem cells remain. However, granulocyte-macrophage colony-stimulating factor (GM-CSF) has not always been effective when administered to patients with severe BM failure, and in most patients only a transient increase in leukocyte and granulocyte counts has been observed [ 14-17]. Prolonged administration of G-CSF alone [ 181 or in combination with either Epo [ 191 or other hematopoietic growth factors, such as stem cell factor, interleukin 1 (IL-1) and IL , or with immunosuppressive agents, such as cyclosporine or antithymocyte globulin [2-251, may hold promise in restoring hematopoiesis in the BM. Although 6 of 12 reported patients with myelodysplastic syndrome (MDS) had detectable or elevated levels in the peripheral blood serum [6], the subtype of MDS was not delineated. Our study revealed insignificant elevations of BM plasma G-CSF level in RA patients, but lower elevations than those found in AA patients, although another study revealed no elevation in the peripheral blood serum [26]. These results suggest the possibility that G-CSF is clinically useful in RA patients. Indeed, the administration of GM-CSF or G-CSF in patients with RA has been found to substantially increase the numbers of leukocytes and granulocytes during administration [27-11, although they decreased to the pretreatment level after discontinuation, indicating that maintenance treatment is necessary [0]. The G-CSF level in the MM patients in our study was moderately elevated while it was found to be elevated in another study [6]. The anemia in MM is well controlled by administration of Epo [2], as neutropenia may be by G-CSF. The G-CSF level in 2 of the Agra patients was extremely high. There is a report of increased G-CSF levels in patients with acute infection without hematological disorders []. Our data in Agra patients indicate that the nadir phase of granulopoiesis is associated with infection. The reason for the variation in G-CSF levels among AML FAB subgroups and the absence of any relationship between these levels and the percentages of myeloblasts in the BM remains to be solved. Leukemic myeloblasts have the receptor for G-CSF [4]. High peripheral blood G-CSF levels have been reported for the patients with M4 and MS subgroups [S]. There is a wide variation in the frequency of spontaneous colony formation in vitro, depending on the patient and FAB subgroup [5]. Leukemic myeloblasts secrete GM-CSF as well as G-CSF [6], and show autocrine growth [5-71 as well as paracrine growth 181 in response to the secreted cytokines. Our results may represent the diversity of response to G-CSF by each type of leukemic myeloblast in vitro. The G-CSF levels in ALL and CLL patients were normal, and the growth of these cells may not be affected by G-CSF. In our patient with CMML, the G-CSF level was high before chemotherapy but returned to normal after the patient entered complete remission. The conditioned medium of the CMML cells contained elevated amounts of IL-6 and GM-CSF, suggesting that these act in vitro as autocrine growth factors for CMML cells [9, 401. Our results suggest that G-CSF may also be involved in this process. Most of our patients with CML showed significantly decreased BM plasma G-CSF levels, and one patient who had a normal level was under a-interferon therapy and in hematological remission, as in another report [6]. The peripheral blood serum G-CSF level has been reported to be undetectable in almost all CML patients, except a few with elevated G-CSF levels [S, 61. The reason for this difference is unknown. The significantly decreased G-CSF levels in these disorders indicate the presence of a negative feedback mechanism in the control of granulopoiesis. The G-CSF level in the PV patients was not significantly decreased. In general, the BM plasma G-CSF level is inversely correlated with the percentages of
6 Shinohara et al. 426 myeloid cells in the BM smear, as peripheral blood serum G-CSF is inversely correlated with the absolute neutrophil count in patients with AA [6] and as we found in the BM plasma. These results for the BM plasma G-CSF level may more directly reflect the pathophysiological mechanisms of disordered granulopoiesis than do those for the G-CSF level of the peripheral blood plasma. We conclude that our method of G-CSF measurement may facilitate the understanding of hematological disorders from the standpoint of granulopoiesis and the selection of candidates who are likely to benefit from the clinical use of G-CSF. References 1 Zsebo KM, Yuschenkoff VN, Schiffer S et al. Vascular endothelial cells and granulopoiesis: interleukin 1 stimulates release of G-CSF and GM-CSF. Blood 1988;71: Fiebbe WE, van Damme J, Billaian A et al. Interleukin I induces human marrow stromal cells in long-term culture to produce granulocyte colony-stimulating factor and macrophage colonystimulating factor. Blood 1988;71: Yang Y-C, Tsai S, Wong GG et al. Interleukin 1 regulation of hematopoietic growth factor production by human stromal fibroblasts. J Cell Physiol 1988;14: Sallerfors B, Olofesson T. Granulocytemacrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) in serum during induction treatment of acute leukemia. Br J Haematol 1991;78: Omori F, Okamura S, Shimoda K et al. Levels of human serum granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimdating factor under pathological conditions. Biotherapy 1992;4: Watari K, Asano S, Shirafuji N et al. Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood 1989;7: Haas R, Gericke G, Witt B et al. Increased serum levels of granulocyte colony-stimulating factor after autologous bone marrow or blood stem cell transplantation. Exp Hematol 199;21: Miksitis K, Beyer J, Siegert W. Serum concentrations of G-CSF during high-dose chemotherapy with autologous stem cell rescue. Bone Marrow Transplant 199;11: Ichikawa T, Kuwaki T, Tachibana K et al. Establishment of a highly sensitive enzyme immunoassay for granulocyte colony-stimulating factor in human plasma. Exp Hematol (in press). Dacie JV, Lewis SM, eds. Practical Haematology. Edinburgh: Churchill Livingstone, Cairo MS, Suen Y, Sender L et al. Circulating granulocyte colony-stimulating factor (G-CSF) levels after allogeneic and autologous bone marrow transplantation: endogenous G-CSF production correlates with myeloid engraftment. Blood 1992;79: Bessho M, Jinnai I, Matsuda A et al. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. Int J Cell Cloning 1990;8: Urabe A, Saito T, Fukamachi H et al. Serum erythropoietin titers in the anemia of chronic renal failure and other hematological states. Int J Cell Cloning 1987;5: Vadhan-Raj S, Buescher S, Broxmeyer HE et al. Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factor. N Engl J Med 1988;19: Nissen C, Tichelli A, Gratwohl A et al. Failure of recombinant human granulocyte-macrophage colony-stimulating factor therapy in aplastic anemia patients with very severe neutropenia. Blood 1988;72: Champlin RE, Nimer SD, Ireland D et al. Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophagecolony-stimulating factor. Blood 1989;7: Guinan EC, Sieff CA, Oette DH et al. A phase YII trial of recombinant granulocyte-macrophage colony-stimulating factor for children with aplastic anemia. Blood 1990;76: Kojima S, Fukuda M, Miyajima Y et a]. Treatment of aplastic anemia in children with recombinant human granulocyte colony-stimulating factor. Blood 1991;77: Bessho M, Toyoda A, Ito Y et al. Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor (rhg-csf) and erythropoietin (rhepo) in severe aplastic anemia. Br J Haematol 1992;80: Williams DA. Ex vivo expansion of hematopoietic stem and progenitor cells. Blood 199;81: Srour EF, Brandt JE, Briddell RA et al. Long-term generation and expansion of human primitive
7 427 The Levels of G-CSF in the Plasma of the Bone Marrow Aspirate in Various Hematological Disorders hematopoietic progenitor cells in vitro. Blood 199;81 : Muench MO, Firpo MT, Moore MAS. Bone marrow transplantation with interleukin l plus kitligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferative potential. Blood 199;81: Kojima S, Fukuda M, Miyajima Y et al. Cyclosporine and recombinant granulocyte colony-stimulating factor in severe aplastic anemia. N Engl J Med 1990;2: Bertrand Y, Amri F, Capdeville R et al. The successful treatment of two cases of severe aplastic anemia with granulocyte-colony stimulating factor and cyclosporine A. Br J Haematol 1991 ;79: Doney K, Storb R, Appelbaum FR et al. Recombinant granulocyte-macrophage colony stimulating factor followed by immunosuppressive therapy for aplastic anemia. Br J Haematol 199;85: Verhoef GEG, Schouwer PD, Ceuppens JL et al. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 1992;6: Vadhan-Raj S, Keating M, LeMaistre A et al. Effects of recombinant human granulocytemacrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 1987;17: Ganser A, Volkers B, Greher J et al. Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes-a phase YII trial. Blood 1989;7: Kobayashi Y, Okabe T, Ozawa K et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: a preliminary report. Am J Med 1989;86: Negrin RS, Haeuber DH, Negler A et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 1990:76: Yoshida Y, Hirashima K, Asano S et al. A phase I1 trial of recombinant human granulocyte colonystimulating factor in the myelodysplastic syndromes. Br J Haematol 1991;78: Ludwig H, Fritz E, Kotzrnann H et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;22: Kawakami M, Tsutsumi H, Kumakawa T et al. Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood 1990;76: Piao YF, Okabe T. Receptor binding of human granulocyte-colony stimulating factor to the blast cells of myeloid leukemia. Cancer Res 1990;50: Young DC, Wagner K, Griffin JD. Constitutive expression of the granulocyte-macrophage colonystimulating factor gene in acute rnyeloblastic leukemia. J Clin Invest 1987;79: Young DC, Griffin JD. Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood 1986;68: Murohashi I, Tohda S, Suzuki T et al. Autocrine growth mechanisms of the progenitors of blast cells in acute myeloblastic leukemia. Blood 1989;74: Oster W, Cicco NA, Klein H et al. Participation of the cytokines interleukin 6, tumor necrosis factora, and interleukin I-p secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J Clin Invest 1989;84: Everson MP, Brown CB, Lilly MB. Interleukin 6 and granulocyte-macrophage colony-stimulating factor are candidate growth factors for chronic myelomonocytic leukemia cells. Blood 1989;74: Akashi K, Shibuya T, Harada M et al. Interleukin 4 suppresses the spontaneous growth of chronic myelomonocytic leukemia cells. J Clin Invest 1991 ;88:22-20.
Effect of Interleukin 10 on the Hematopoietic Progenitor Cells from Patients with Aplastic Anemia
Effect of Interleukin 10 on the Hematopoietic Progenitor Cells from Patients with Aplastic Anemia YOSHINOBU ASANO, SHOICHIRO SHIBATA, SHINJI KOBAYASHI, SEIICHI OKAMURA, YOSHIYUKI NIHO First Department
More informationHematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte-macrophage colonystimulating factor (G-CSF).
Hematopoietic Growth Factors Colony Stimulating Factors. Erythropoietin (Epoetin alfa). Granulocyte colony-stimulating factor(g-csf). Granulocyte-macrophage colonystimulating factor (G-CSF). Interleukin-11
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.08 Subject: Leukine Page: 1 of 6 Last Review Date: March 13, 2014 Leukine Description Leukine (sargramostim)
More informationLeukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.08 Subject: Leukine Page: 1 of 5 Last Review Date: September 15, 2017 Leukine Description Leukine
More informationInterleukin-l Production in Patients with Nonlymphocytic Leukemia and Myelodysplastic Syndromes
Interleukin-l Production in Patients with Nonlymphocytic Leukemia and Myelodysplastic Syndromes N. J. Simbirtseva 1 A common feature of all cases of myeloid leukemia is a block in normal maturation of
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 6 Last Review Date: September 15, 2017 Granix Description Granix (tbo-filgrastim)
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 7 Last Review Date: December 2, 2016 Granix Description Granix (tbo-filgrastim)
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Subject: Granix 1 of 7 Last Review Date: September 18, 2015 Granix Description Granix (tbo-filgrastim)
More informationHematology 101. Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD
Hematology 101 Blanche P Alter, MD, MPH, FAAP Clinical Genetics Branch Division of Cancer Epidemiology and Genetics Bethesda, MD Hematocrits Plasma White cells Red cells Normal, Hemorrhage, IDA, Leukemia,
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Section: Prescription Drugs Effective Date: April 1, 2014 Subject: Granix 1 of 7 Last Review Date:
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
More informationRecombinant Human Erythropoietin (rhuepo) for Treatment of Myelodysplastic Syndrome
Recombinant Human Erythropoietin (rhuepo) for Treatment of Myelodysplastic Syndrome Zella R. Zeigler ", Douglas Jonesb, Craig S. Rosenfeld a, Richard K. Shadduck a *West Penn Hospital, Western Pennsylvania
More informationThe Immune System. A macrophage. ! Functions of the Immune System. ! Types of Immune Responses. ! Organization of the Immune System
The Immune System! Functions of the Immune System! Types of Immune Responses! Organization of the Immune System! Innate Defense Mechanisms! Acquired Defense Mechanisms! Applied Immunology A macrophage
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationClinical Policy: Sargramostim (Leukine) Reference Number: CP.PHAR.295
Clinical Policy: (Leukine) Reference Number: CP.PHAR.295 Effective Date: 12/16 Last Review Date: 10/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationNeupogen (Filgrastim)/Neulasta (Pegfilgrastim)
Policy Number Reimbursement Policy NEU12182013RP Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 12/18/2013 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This
More informationa resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation
a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationProduction of the Formed Elements (Chapter 11) *
OpenStax-CNX module: m62120 1 Production of the Formed Elements (Chapter 11) * Ildar Yakhin Based on Production of the Formed Elements by OpenStax This work is produced by OpenStax-CNX and licensed under
More informationHEMATOLOGIC MALIGNANCIES BIOLOGY
HEMATOLOGIC MALIGNANCIES BIOLOGY Failure of terminal differentiation Failure of differentiated cells to undergo apoptosis Failure to control growth Neoplastic stem cell FAILURE OF TERMINAL DIFFERENTIATION
More informationPATIENTS WITH myelodysplasia (MDS) and other
Pilot Study of Low-Dose Interleukin-11 in Patients With Bone Marrow Failure By Razelle Kurzrock, Jorge Cortes, Deborah A. Thomas, Sima Jeha, Susan Pilat, and Moshe Talpaz Purpose: Interleukin-11 (IL-11)
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationVARIATION OF SERUM G-CSF LEVEL IN APL TREATED WITH ALL-TRANS RETINOIC ACID
Chinese Journal of Cancer Research 11(2): 131 --135, 1999 131 VARIATION OF SERUM G-CSF LEVEL IN APL TREATED WITH ALL-TRANS RETINOIC ACID JANG Guosheng ~ [~ ~,* ZHOU Rongfu N] ~ ~, ZHANG Fenqin.~j:~, SUN
More informationLCD for Sargramostim (GM-CSF, Leukine ) (L29275)
LCD for Sargramostim (GM-CSF, Leukine ) (L29275) Contractor Information Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B LCD ID Number L29275 LCD Information
More informationMPL W515L K mutation
MPL W515L K mutation BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationClinical Utility. Clinical Utility of the Automated IG-Count Xavier Troussard
5. Clinical Utility Clinical Utility of the Automated IG-Count Xavier Troussard Introduction Quantitative analysis of immature granulocytes (IG) is useful for the optimal clinical and biological management
More informationPathology. #11 Acute Leukemias. Farah Banyhany. Dr. Sohaib Al- Khatib 23/2/16
35 Pathology #11 Acute Leukemias Farah Banyhany Dr. Sohaib Al- Khatib 23/2/16 1 Salam First of all, this tafreegh is NOT as long as you may think. If you just focus while studying this, everything will
More informationHematopoietic Stem Cells, Stem Cell Processing, and Transplantation
Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, M irector, Hemotherapy and Stem Cell Processing Facility Bone Marrow Can Cure: Leukemia Lymphoma Multiple Myeloma Genetic iseases:
More informationGroup of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and
Group of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and / or peripheral blood Classified based on cell type
More informationHemopoietic Precursors in Human Bone Marrow Transplantation
International Journal of Cell Cloning 4: 11-18 Suppl 1 (1986) Hemopoietic Precursors in Human Bone Marrow Transplantation H.A. Messner Ontario Cancer Institute, University of Toronto, Toronto, Ontario,
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationDifferentiation Ability of Peripheral Blood Cells from Patients with Acute Leukemia or Blast Crisis in Chronic Myelocytic Leukemia"
Differentiation Ability of Peripheral Blood Cells from Patients with Acute Leukemia or Blast Crisis in Chronic Myelocytic Leukemia" Hoelzer, D.,l, Harriss, E. B.l, Kurrle, E.l, Schmücker, H.l, Hellriegel,
More informationProduction of the Formed Elements *
OpenStax-CNX module: m46691 1 Production of the Formed Elements * OpenStax This work is produced by OpenStax-CNX and licensed under the Creative Commons Attribution License 3.0 By the end of this section,
More informationIntroduction to Hematopoietic Stem Cell Transplantation
Faculty Disclosures Introduction to Hematopoietic Stem Cell Transplantation Nothing to disclose Jeanne McCarthy-Kaiser, PharmD, BCOP Clinical Pharmacist, Autologous Stem Cell Transplant/Long- Term Follow-Up
More informationPathology of Hematopoietic and Lymphoid tissue
CONTENTS Pathology of Hematopoietic and Lymphoid tissue White blood cells and lymph nodes Quantitative disorder of white blood cells Reactive lymphadenopathies Infectious lymphadenitis Tumor metastasis
More informationClinical Policy: Donor Lymphocyte Infusion
Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte
More informationWhat is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification
What is MDS? Epidemiology, Diagnosis, Classification & Risk Stratification Rami Komrokji, MD Clinical Director Malignant Hematology Moffitt Cancer Center Normal Blood and Bone Marrow What is MDS Myelodysplastic
More informationBMTCN Review Course Basic Concepts and Indications for Transplantation How the Experts Treat Hematologic Malignancies Las Vegas, NV, March 10, 2016
BMTCN Review Course Basic Concepts and Indications for Transplantation How the Experts Treat Hematologic Malignancies Las Vegas, NV, March 10, 2016 David Rice, PhD, RN, NP Director, Professional Practice
More informationCHAPTER:4 LEUKEMIA. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY 8/12/2009
LEUKEMIA CHAPTER:4 1 BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Leukemia A group of malignant disorders affecting the blood and blood-forming tissues of
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationIn Vitro Growth of Erythropoietic Progenitor Cells in Long-%rm Remission of Acute Leukemia
International Journal of Cell Cloning 4: 186-191 (1986) In Vitro Growth of Erythropoietic Progenitor Cells in Long-%rm Remission of Acute Leukemia C. Peschel, G. Konwalinka, D. Geissler, H. Bmunsteiner
More informationMyelodysplastic Syndromes: Everyday Challenges and Pitfalls
Myelodysplastic Syndromes: Everyday Challenges and Pitfalls Kathryn Foucar, MD kfoucar@salud.unm.edu Henry Moon lecture May 2007 Outline Definition Conceptual overview; pathophysiologic mechanisms Incidence,
More informationMDS - Diagnosis and Treatments. Dr Helen Enright, Adelaide and Meath Hospital Dr Catherine Flynn, St James Hospital
MDS - Diagnosis and Treatments Dr Helen Enright, Adelaide and Meath Hospital Dr Catherine Flynn, St James Hospital Overview What is myelodysplasia? Symptoms Diagnosis and prognosis Myelodysplasia therapy
More informationmyelodysplastic syndrome MDS MDS MDS
myelodysplastic syndrome MDS MDS 15 10 3 2004 15 MDS 400 2 65 61 70 MDS MDS 1 1 2 3 3 4 1 4 2 3 4 MDS 1982 Bennett French- American-BritishFAB 1 2 WHO 1999 3 2001 4 2002 Vardiman MDS 5 2WHO FAB refractory
More informationWhat is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements
More informationPathology of Hematopoietic and Lymphoid tissue
Pathology of Hematopoietic and Lymphoid tissue Peerayut Sitthichaiyakul, M.D. Department of Pathology and Forensic Medicine Faculty of Medicine, Naresuan University CONTENTS White blood cells and lymph
More informationMYELODYSPLASTIC AND MYELOPROLIFERATIVE
MYELODYSPLASTIC AND MYELOPROLIFERATIVE DISORDERS Pediatric Hemato-Oncology Division Medical Faculty University of Sumatera Utara 1 MYELODYSPLASIA SYNDROME A group of disorder defect in hematopoetic cell
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
More informationEvaluation of Early Post-transplant Leukocyte Recovery Using the Undiluted Erythrocyte Lysing Technique
Annals of Clinical & Laboratory Science, vol. 32, no. 2, 2002 159 Evaluation of Early Post-transplant Leukocyte Recovery Using the Undiluted Erythrocyte Lysing Technique Myungshin Kim, 1 Ja Young Kim,
More informationSystematic Reviews in Hematological Malignancies
Systematic Reviews in Hematological Malignancies Pia Raanani, MD Davidoff Cancer Center Rabin Medical Center, Israel 1 2 Disorder CHMG Systematic review* Title Protocol Full Review Myelodysplastic syndrome
More informationClassification of Hematologic Malignancies. Patricia Aoun MD MPH
Classification of Hematologic Malignancies Patricia Aoun MD MPH Objectives Know the basic principles of the current classification system for hematopoietic and lymphoid malignancies Understand the differences
More informationWBCs Disorders 1. Dr. Nabila Hamdi MD, PhD
WBCs Disorders 1 Dr. Nabila Hamdi MD, PhD ILOs Compare and contrast ALL, AML, CLL, CML in terms of age distribution, cytogenetics, morphology, immunophenotyping, laboratory diagnosis clinical features
More information2. Is therapy prescribed by, or in consultation with, a hematologist and/or oncologist?
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationMap kinase signaling pathways and hematologic malignancies
Review in translational hematology Map kinase signaling pathways and hematologic malignancies Leonidas C. Platanias Introduction Mitogen-activated protein (Map) kinases are widely expressed serine-threonine
More informationFor peripheral blood stem cell (PBSC) mobilization prior to and during leukapheresis in cancer patients preparing to undergo bone marrow ablation
Last Review: 4/2010 NON-FORMULARY Clinical Guideline Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF), Neumega (oprelvekin; rh-il-11), Leukine (sargramostim; GM-CSF) Indications Neupogen
More informationMyelodyplastic Syndromes Paul J. Shami, M.D.
Myelodyplastic Syndromes Paul J. Shami, M.D. Professor of Hematology, University of Utah Member, Huntsman Cancer Institute Objectives Define Myelodysplastic Syndromes (MDS) Explain how MDS are diagnosed
More informationAplastic anemia. Case report. Effect of antithymocyte globulin on erythroid colony formation
Case report Aplastic anemia Effect of antithymocyte globulin on erythroid colony formation Susan A. Rothmann Hamburger, Ph.D. Department of Laboratory Hematology and Blood Banking James H. Finke, Ph.D.
More informationBMTCN Review Course Basic Concepts and Indications for Transplantation. David Rice, PhD, RN, NP
BMTCN Review Course Basic Concepts and Indications for Transplantation March 16, 2017 David Rice, PhD, RN, NP Director, Professional Practice and Education No disclosures Objectives Describe basic concepts
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationCynthia Fata, MD, MSPH 6/23/15
Cynthia Fata, MD, MSPH 6/23/15 Clinical case presentation Introduction to thrombopoietin Development of thrombopoietic agents Clinical Indications Eltrombopag use in aplastic anemia Future uses 33 yo F
More informationHematology Unit Lab 2 Review Material
Objectives Hematology Unit Lab 2 Review Material - 2018 Laboratory Instructors: 1. Assist students during lab session Students: 1. Review the introductory material 2. Study the case histories provided
More informationبسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم WBCs disorders *Slide 2: - we will focus on the disorders that are related to the # of WBCs - in children the # of lymphocyte is more than it in adults,sometimes more than neutrophils
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationAcute myeloid leukemia. M. Kaźmierczak 2016
Acute myeloid leukemia M. Kaźmierczak 2016 Acute myeloid leukemia Malignant clonal disorder of immature hematopoietic cells characterized by clonal proliferation of abnormal blast cells and impaired production
More informationJAK2 V617F analysis. Indication: monitoring of therapy
JAK2 V617F analysis BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationHematopoietic Stem Cell Therapy
Hematopoietic Stem Cell Therapy Grace Totoe, MBChB, SBB CME August 2012 Accra-Ghana Hematopoietic Stem Cells Cells capable of self renewal and differentiation into all blood cell lineages Objectives Historical
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1 of 6 Last Review Date: March 16, 2018 Tasigna Description Tasigna (nilotinib)
More informationMYELODYSPLASTIC SYNDROMES
MYELODYSPLASTIC SYNDROMES Babak Tamizi Far MD. Assistant professor of internal medicine Al-zahra university hospital, Isfahan university of medical sciences Key Features ESSENTIALS OF DIAGNOSIS Cytopenias
More informationTasigna. Tasigna (nilotinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.77 Subject: Tasigna Page: 1of 5 Last Review Date: September 15, 2017 Tasigna Description Tasigna (nilotinib)
More informationPeking University People's Hospital, Peking University Institute of Hematology
Qian Jiang, M.D. Peking University People's Hospital, Peking University Institute of Hematology No. 11 Xizhimen South Street, Beijing, 100044, China. Phone number: 86-10-66583802 Mobile: 86-13611115100
More informationcolorimetric sandwich ELISA kit datasheet
colorimetric sandwich ELISA kit datasheet For the quantitative detection of human IL5 in serum, plasma, cell culture supernatants and urine. general information Catalogue Number Product Name Species cross-reactivity
More informationLay Summaries ASH 2017
Lay Summaries ASH 2017 Purpose of Document: This document contains a collection of lay summaries of accepted ASH 2017 abstracts from the following investigators: MDS CRC Members/Affiliates, Fellows (past
More informationThe AML subtypes are based on how mature (developed) the cancer cells are at the time of diagnosis and how different they are from normal cells.
What is Acute Myeloid Leukemia (AML)? Acute myeloid leukemia (AML) is a cancer of cells in the blood, bone marrow and lymph nodes. AML is also called acute nonlymphocytic leukemia, acute myeloblastic leukemia,
More informationActinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment
More informationMyeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP
Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization MERC CARE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationDonor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of
More informationNational Horizon Scanning Centre. Azacitidine (Vidaza) for myelodysplastic syndrome. September 2007
Azacitidine (Vidaza) for myelodysplastic syndrome September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationAccelerate Your Research with Conversant Bio
Accelerate Your Research with Conversant Bio 400+ Participating MDs 50+ Partner sites for tissue procurement Continuous expansion of sourcing capabilities Closely monitored chain of custody Full regulatory
More informationBone Marrow Morphology after Therapy and Stem Cell Transplantation. Arash Mohtashamian, MD Naval Medical Center, San Diego
Bone Marrow Morphology after Therapy and Stem Cell Transplantation Arash Mohtashamian, MD Naval Medical Center, San Diego Objectives Bone marrow findings after myeloablative therapy. Effects of recombinant
More informationEffects of Prostaglandin E on the Proliferation and Differentiation of Leukemic Progenitor Cells in Acute Nodymphocytic Leukemia
International Journal of Cell Cloning 1 : 440-450 (1983) Effects of Prostaglandin E on the Proliferation and Differentiation of Leukemic Progenitor Cells in Acute Nodymphocytic Leukemia Keiya Ozawa&.l,
More informationCHALLENGING CASES PRESENTATION
CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36
More informationOutline. Case Study 5/17/2010. Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center
Treating Lower-Risk Myelodysplastic Syndrome (MDS) Tapan M. Kadia, MD Department of Leukemia MD Anderson Cancer Center Outline Case Study What is lower-risk MDS? Classification systems Prognosis Treatment
More informationRegence. Next Review: 08/2019 Last Review: 08/2018 Medicare Link(s) Revised: 10/01/2018 IMPORTANT REMINDER
Regence Medicare Advantage Policy Manual Policy ID: M-TRA45 Stem Cell / Bone Marrow Transplants Published: 10/01/2018 Next Review: 08/2019 Last Review: 08/2018 Medicare Link(s) Revised: 10/01/2018 IMPORTANT
More informationHematopoietic Stem Cells
Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, M irector, Hemotherapy and Stem Cell Processing Facility E-mail: js2745@columbia.edu Hematopoietic Stem Cells Sustain hematopoiesis
More informationPrognostic Value of Plasma Interleukin-6 Levels in Patients with Chronic Lymphocytic Leukemia
1071 Prognostic Value of Plasma Interleukin-6 Levels in Patients with Chronic Lymphocytic Leukemia Raymond Lai, M.D, PhD. 1 Susan O Brien, M.D. 2 Taghi Maushouri, M.S. 1 Anna Rogers, 1 Hagop Kantarjian,
More informationBorder between aplastic anemia and myelodysplastic syndrome
Int J Hematol (2013) 97:558 563 DOI 10.1007/s12185-013-1324-x PROGRESS IN HEMATOLOGY Advances in the management of acquired aplastic anemia (AA) Border between aplastic anemia and myelodysplastic syndrome
More informationAdult Acute leukemia. Matthew Seftel. August
Adult Acute leukemia Matthew Seftel August 21 2007 mseftel@cancercare.mb.ca Principles 3 cases Diagnosis and classification of acute leukemia (AL) Therapy Emergencies Remission induction BMT Complications
More informationDr.PSRK.Sastry MD, ECMO
Peripheral blood stem cell transplantation (Haematopoietic stem cell transplantation) Dr.PSRK.Sastry MD, ECMO Consultant, Medical Oncology Kokilaben Dhirubhai Ambani Hospital Normal hematopoiesis Historical
More informationAtomic Bomb and Leukemia ICHIMARU M., TOMONAGA M., AMENOMORI T. AND MATSUO T.
Atomic Bomb and Leukemia ICHIMARU M., TOMONAGA M., AMENOMORI T. AND MATSUO T. Department of Hematology, Atomic Disease Institute, Nagasaki University School of Medicine, Nagasaki, Japan (Received December
More informationPNH Glossary of Terms
AA Absolute neutrophil count Alendronate Allergen ALT Anemia Antibodies Anticoagulant Anticoagulation Antigen Antithymocyte globulin (ATG) Aplastic Aplastic anemia Band Bilirubin Blast cells Bone marrow
More informationImmune Reconstitution Following Hematopoietic Cell Transplant
Immune Reconstitution Following Hematopoietic Cell Transplant Patrick J. Kiel, PharmD, BCPS, BCOP Clinical Pharmacy Specialist Indiana University Simon Cancer Center Conflicts of Interest Speaker Bureau
More informationConcise Review for Primary-Care Physicians
Concise Review for Primary-Care Physicians Myelodysplastic (Preleukemia) Syndromes: The Bone Marrow Factory Failure Problem H. CLARK HOAGLAND, M.D. The myelodysplastic syndromes are a group of hematologic
More informationDone By : WESSEN ADNAN BUTHAINAH AL-MASAEED
Done By : WESSEN ADNAN BUTHAINAH AL-MASAEED Acute Myeloid Leukemia Firstly we ll start with this introduction then enter the title of the lecture, so be ready and let s begin by the name of Allah : We
More information